What is a primary (Ghon) complex in tuberculosis and how is it managed?

Primary (Ghon) Complex in Tuberculosis

Definition and Pathological Features

A primary (Ghon) complex is the characteristic pathological hallmark of initial tuberculosis infection, consisting of a peripheral lung parenchymal focus (Ghon focus) combined with enlarged draining lymph nodes in the hilum or mediastinum. 1 This represents the body's first encounter with Mycobacterium tuberculosis in individuals without prior immunity, typically occurring in children and young adults. 2

Key Anatomical Characteristics:

• The Ghon focus is located close to the pleura in approximately two-thirds of cases, appearing as a single peripheral lung lesion in about 80% of tuberculosis-infected children 3
• Lymphatic spread involves hilar and mediastinal lymph nodes, and may extend to abdominal and cervical nodes in many cases 3
• Cavitation of the primary focus is common, and the complex may show complete calcification when healed 3
• The presence of a Ghon complex on chest radiograph is considered positive for latent tuberculosis, while a Ghon complex with enlarged mediastinal lymph nodes typically indicates active primary tuberculosis 1

Clinical Significance and Diagnostic Implications

When a Ghon complex is identified on chest imaging, immediate assessment for active versus latent tuberculosis is mandatory. 1

Diagnostic Algorithm:

• If Ghon complex appears with enlarged mediastinal lymph nodes: presume active primary tuberculosis and obtain sputum for acid-fast bacilli smear and culture 1
• If Ghon complex shows only scarring without lymphadenopathy: assess for latent tuberculosis infection with tuberculin skin test (TST) or interferon-gamma release assay (IGRA), plus clinical evaluation for symptoms 1
• Evaluate for fever, night sweats, weight loss, cough, and hemoptysis to distinguish active from latent disease 4

Management Based on Disease Activity

Active Primary Tuberculosis (Ghon Complex + Lymphadenopathy + Symptoms)

Treat with the standard six-month four-drug regimen: rifampicin, isoniazid, pyrazinamide, and ethambutol for two months, followed by rifampicin and isoniazid for four additional months. 5, 6, 7

Initial Phase (2 months):

• Rifampicin: 450 mg daily (<50 kg) or 600 mg daily (≥50 kg) 5, 7
• Isoniazid: 300 mg daily 5, 7
• Pyrazinamide: 1.5 g daily (<50 kg) or 2.0 g daily (≥50 kg) 5, 7
• Ethambutol: 15 mg/kg daily 5, 7

Continuation Phase (4 months):

• Rifampicin and isoniazid at the same doses 5, 7

This six-month regimen is as effective as longer nine-month courses for primary tuberculosis and peripheral lymph node disease. 5, 7

Pediatric Dosing:

• Isoniazid 5 mg/kg, rifampicin 10 mg/kg, pyrazinamide 35 mg/kg, ethambutol 15 mg/kg for the same six-month duration 7

Latent Tuberculosis (Ghon Complex Without Active Disease)

If the chest radiograph shows only a healed Ghon complex without lymphadenopathy and the patient has a positive TST/IGRA without symptoms, treat for latent tuberculosis infection. 1, 4

Preferred Regimens:

• Isoniazid 300 mg daily for 6-9 months (add pyridoxine 25 mg daily to prevent peripheral neuropathy) 1, 4
• Rifampin 600 mg daily for 4 months as an alternative 1, 4
• Rifampin plus isoniazid combined for 3-4 months in selected cases 4

Mandatory Pre-Treatment Assessments

Before initiating any tuberculosis therapy, obtain baseline liver function tests (AST, ALT, bilirubin) and visual acuity testing if ethambutol will be used. 5, 7, 4

• Renal function evaluation is required before using ethambutol, with dose adjustments needed in renal impairment 5, 4
• Instruct patients to stop ethambutol immediately if visual changes occur 5, 7, 4

Monitoring During Treatment

Liver Function Monitoring:

• Patients with normal baseline liver function: routine monitoring is not required; repeat testing only if symptoms develop (fever, malaise, vomiting, jaundice) 5, 4
• Patients with chronic liver disease: monitor liver enzymes weekly for the first 2 weeks, then every 2 weeks for the first 2 months 5, 4
• Discontinue rifampicin, isoniazid, and pyrazinamide if AST/ALT rise to ≥5× upper limit of normal or if bilirubin rises 5, 4

Clinical Response:

• Paradoxical reactions (enlargement of nodes or appearance of new nodes) are common during or after therapy and do NOT indicate treatment failure—continue the prescribed regimen 5, 7
• After 3 months of therapy, 90-95% of patients should have negative cultures and show clinical improvement 8

Critical Pitfalls to Avoid

• Never treat a Ghon complex with single-drug therapy without first excluding active tuberculosis—this can cause drug resistance 1, 4
• Do not extend treatment beyond 6 months for uncomplicated primary tuberculosis unless pyrazinamide cannot be used (then extend to 9 months) 5, 7
• Do not mistake paradoxical lymph node enlargement for treatment failure—this is a common immune phenomenon that does not require treatment modification 5, 7
• Always obtain mycobacterial cultures before starting therapy to detect drug resistance 8, 5
• In children, distinguish tuberculous from nontuberculous mycobacterial (NTM) infection, as most cervical lymphadenitis in U.S. children is caused by NTM rather than M. tuberculosis 7

Special Populations

HIV-Positive Patients:

• Rifampicin markedly reduces protease-inhibitor levels via CYP3A induction 9, 7
• Preferred approach: discontinue the protease inhibitor and use alternative antiretroviral agents during TB treatment 7
• Alternative: substitute rifabutin for rifampicin with appropriate dose adjustments 9, 7

Renal Impairment:

• Administer all TB medications after hemodialysis on dialysis days to avoid premature drug removal 4
• Reduce ethambutol to 15-25 mg/kg three times weekly (not daily) in end-stage renal disease 4